Hydroxychloroquine recommendations toward the world: first evaluations

Author list: Yanis ROUSSEL$^{1,2}$, Didier RAOULT$^{1,2}$

Affiliations:

1 Institut Hospitalo-universitaire Méditerranée Infection, Marseille, France.
2 Aix Marseille Université, Institut de Recherche pour le Développement (IRD), Assistance Publique-Hôpitaux de Marseille, Evolution Phylogénie et Infections (MEPHI).

Corresponding author: Didier Raoult, IHU Méditerranée Infection, Faculté de Médecine, Aix-Marseille Université, 27 Boulevard Jean Moulin, 13385 Marseille CEDEX 5, France. Tel: +33 (0)4 91 32 43 75; fax: +33 (0)4 91 38 77 72. Email: didier.raoult@gmail.com
SARS-COV2 is an infection caused by a new virus for which no antiviral treatment was known when it first emerged. Since the publication of the first results, from China, on the use of chloroquine and its derivatives in vitro (1) and in vivo (2), then the publication of the trial led in Marseille on the combined use of hydroxychloroquine and azithromycin (3), many countries have adopted this treatment to treat patients with SARS-COV2. Over 60% of humans worldwide live in a country where chloroquine and its derivatives are recommended to treat patients with SARS-COV2. Other countries, waiting for the results of clinical trials to define their strategy, or worried about potential side effects that have not been demonstrated, have favored other treatments or the standard of care. This has not stopped practitioners in these countries from turning massively to hydroxychloroquine as a treatment for SARS-COV2, as shown by the results of surveys by the specialized institute SERMO (4).

Today, now that the epidemic is in a phase of decline in most of the hardest hit countries (5), we can issue initial assessments of the treatment strategies adopted in the world according to the mortality of each of the country. We therefore determined which countries recommended hydroxychloroquine using the recommendations issued by the authorities of these countries as source, identifying among them those who had a late use (after the peak of the epidemic) of this treatment (Figure 1a). Following this work, we established a second map which identifies the 15 countries most affected by the epidemic (in number of deaths per million inhabitants), then the top 16-30 of the countries most affected by the epidemic (Figure 1b).

A comparison of these two maps shows that developing countries have massively turned to the use of hydroxychloroquine, as well as Asian countries which present low mortality by SARS-COV2, despite the fact that they have been the first to be affected by the epidemic. These countries have in common the early adoption of treatments based on hydroxychloroquine and chloroquine, whether or not combined with other antivirals. The countries having expressed the concerns for its use are mainly rich countries (France, Germany, United States). It should be noted that Chinese studies show
that China has adopted aggressive strategies against the virus in its treatment protocols, often combining up to three antivirals (6). This therefore shows a discrepancy between the strategies of the Western world and those of developing countries and the Far East, some being much more cautious than others with regard to the use of treatments to fight against the epidemic. The opposite distribution of chloroquine recommendation and fatality rate is striking. However, there is a correlation but given the multiple factors affecting the epidemics and the fatality rate, no direct caused effect could be claimed.

References


(4) SERMO, Real-time Barometer Data, updated at https://app.sermo.com/covid19-barometer


Funding and Acknowledgements

This work was supported by the French Government under the “Investments for the Future” programme managed by the National Agency for Research (ANR), Méditerranée-Infection 10-IAHU-03.

Figures

Figure 1a: countries recommending the use of hydroxychloroquine to treat patients infected with SARS-COV2. (red: early recommendation; orange: late recommendation)
Figure 1b: Top 15 of countries with the highest mortality per million inhabitants (red), Top 16-30 of the countries with the highest mortality per million inhabitants (orange), source Johns Hopkins University on June 3, 2020.